| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 84,069 | 81,803 | 73,463 | 71,743 |
| Cost of revenue | 48,557 | 47,368 | 45,117 | 44,972 |
| Gross profit | 35,512 | 34,435 | 28,346 | 26,771 |
| Research and development | 13,860 | 13,480 | 12,395 | 11,783 |
| Selling and marketing | 11,642 | 12,286 | 8,465 | 9,124 |
| General and administrative | 23,335 | 26,392 | 25,291 | 20,950 |
| Amortization of intangible assets | 2,025 | 1,990 | 1,990 | 1,993 |
| Total operating expenses | 50,862 | 54,148 | 48,141 | 43,850 |
| Operating loss | -15,350 | -19,713 | -19,795 | -17,079 |
| Impairment of available-for-sale debt securities | - | - | - | 10,073 |
| Interest income | 7,874 | 8,091 | 8,018 | 8,090 |
| Interest expense | 28 | 17 | 14 | 14 |
| Impairment loss | - | 9,926 | - | - |
| Other (expense) income, net | -5 | 46 | 68 | 544 |
| Total other income (expense), net | 7,841 | -1,806 | 8,072 | -1,453 |
| Loss before income taxes | -7,509 | -21,519 | -11,723 | -18,532 |
| Benefit from income taxes | -683 | -2,263 | 176 | -3,838 |
| Net loss from consolidated operations | -6,826 | -19,256 | -11,899 | -14,694 |
| Net loss attributable to noncontrolling interests | -218 | -299 | -369 | -46 |
| Net loss attributable to fulgent | -6,608 | -18,957 | -11,530 | -14,648 |
| Weighted average number of shares outstanding, basic, total | 30,749,000 | 30,544,000 | 30,832,000 | 30,416,000 |
| Weighted average number of shares outstanding, diluted, total | 30,749,000 | 30,544,000 | 30,832,000 | 30,416,000 |
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)